All In Biotech

Drug Trial Radar · NCT04897412

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

A 2-Stage Adaptive Design, Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal and Thigh Subcutaneous Fat (Stage 2)

Last checked: Nov 19, 2026Latest source record: Apr 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Feb 14, 2022

Primary completion

Feb 22, 2023

Study completion Mar 22, 2023

Sponsor

Sponsor type
Industry
First posted
May 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Stage 2 of this phase 2 study will be a randomized, single-blind, placebo-controlled, parallel, and multiple-dose study to assess the efficacy, safety, and subject satisfaction of CBL-514.

Conditions

  • Subcutaneous Fat

Interventions

  • CBL-514 InjectionDrug

    Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.

  • PlaceboOther

    Sodium Chloride (0.9% NaCl) placebo for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who lose at least 150 mL of subcutaneous fat compared with placeboTime frame: From Visit 2 (Baseline) up to 8 weeks after last treatment

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational site 1

    Chicago, Illinois

  • Investigational site 2

    Omaha, Nebraska

  • Investigational site 3

    Nashville, Tennessee

  • Investigational site 4

    Austin, Texas

  • Investigational site 5

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.